Nottingham-based cancer detection company Oncimmune Holdings has acquired a business in Germany for a total consideration of up to £4.11m.
Dortmund-based Protagen Diagnostics AG develops precision medicine and patient stratification tools for pharmaceutical multinationals in both immuno-oncology and autoimmune disease.
These tools support drug development, improve treatment strategies and patient management.
Oncimmune has said it intends to retain Protagen’s scientific team and the Dortmund laboratory to operate as its discovery research centre.
It added that Oncimmune’s Nottingham and Kansas facilities will continue to be responsible for the enlarged group’s product development, validation and production.
Chief executive Adam Hill said: “The acquisition of Protagen will accelerate Oncimmune’s product discovery process, will grow our library of known and novel immunogenic proteins, and will underpin the group’s ability to deliver value through the development of complementary diagnostics, a key component of our three-year forward strategy.
“Protagen’s biomarker discovery expertise and high throughput antigen screening technology are all highly synergistic to Oncimmune’s current capabilities. I look forward to working with our new colleagues to grow our company.”
By Jon Robinson
Source: Insider Media
Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.
Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice.
When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.
